1-18 of 18 results for subject:Finance
Librarians' tools
- Search time
- 0.217 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Finance
- We searched for
- subject_t:Finance OR subject_ses:91257
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Hewitt, Patricia (18)
Legislative stage
Legislation
Subject
More
Medical treatments (18)
Publisher
My hon. Friend makes an extremely important point. In striking contrast to the scaremongering that we get from the Conservative party about 20,000 redundancies, over the current financial year there have been just over 1,400 redundancies, the great majority in management and administrative jobs. Although it is of course difficult for the individuals concerned—we are ensuring that the NHS supports them in these difficult times—it is a very different picture from what the Conservative party and some of the media have been telling people.
My hon. Friend makes an extremely important point. In striking contrast to the scaremongering that we get from the Conservative party about 20,000 redundancies, over the current financial year there have been just over 1,400 redundancies, the great majority in management and administrative jobs. Although it is of course difficult for the individuals concerned—we are ensuring that the NHS supports them in these difficult times—it is a very different picture from what the Conservative party and some of the media have been telling people.
Answered by
Patricia Hewitt
(Labour)
Asked by
Charlotte Atkins
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
Is my hospital trust typical? The university hospital of North Staffordshire announced 1,000 redundancies as a result of its deficit, but ultimately only 150 redundancies resulted, two thirds of which were voluntary. Clearly, any redundancy is a matter of regret, particularly in an area like north Staffordshire, but where does that leave the Opposition’s claims of 20,000 redundancies nationwide?
Subjects
Finance; NHS; Medical treatments; NHS trusts; Redundancy; Surgery
Date
13 March 2007
Reference
458 c151
Chamber / Committee
House of Commons chamber
House
House of Commons
I very much regret the fact that the hon. Gentleman completely fails to pay credit to the NHS managers and staff who, in a very difficult year, have got a grip on NHS finances and will achieve financial balance at the end of this month, putting the NHS in a far stronger position. May I suggest that he has a word with his hon. Friend the Member for South Cambridgeshire (Mr. Lansley), just two seats along, who told the House only yesterday that it was the statutory responsibility of—
I very much regret the fact that the hon. Gentleman completely fails to pay credit to the NHS managers and staff who, in a very difficult year, have got a grip on NHS finances and will achieve financial balance at the end of this month, putting the NHS in a far stronger position. May I suggest that he has a word with his hon. Friend the Member for South Cambridgeshire (Mr. Lansley), just two seats along, who told the House only yesterday that it was the statutory responsibility of—
Answered by
Patricia Hewitt
(Labour)
Asked by
Tim Loughton
(Conservative)
Answering body
Department of Health
Type
Oral answers to questions
What the hon. Member for Somerton and Frome (Mr. Heath) failed to mention was that the Health Service Journal survey also revealed that seven out of 10 PCT chief executives agreed that patient care would suffer because of restricting access to treatments. Does the Secretary of State think that they should be applauded as good financial planners, encouraged by her Department to fudge the books and please the accountants, or is it a false economy that forces consultants to twiddle their thumbs for several months while sick patients are denied the treatments that they need?
Subjects
Finance; NHS; Medical treatments; NHS trusts; Redundancy; Surgery
Date
13 March 2007
Reference
458 c151
Chamber / Committee
House of Commons chamber
House
House of Commons
At least the hon. Gentleman and his party voted for those extra resources. I am surprised, however, that he did not refer to the fact that the NHS in Somerset will get additional funding of almost £120 million over the current year and next year. That is being reflected in the improvements taking place in Minehead hospital, the new cancer centre in Taunton and Somerset and the new community hospital at Frome. We believe that what we need is fair funding for the NHS—record funding for the NHS—and the best care for patients within the budget available. I know that the Liberal party has never been very keen on sound public finances or value for money, but the Government will continue to ensure that patients get the best possible value from the record investment that we have made.
At least the hon. Gentleman and his party voted for those extra resources. I am surprised, however, that he did not refer to the fact that the NHS in Somerset will get additional funding of almost £120 million over the current year and next year. That is being reflected in the improvements taking place in Minehead hospital, the new cancer centre in Taunton and Somerset and the new community hospital at Frome. We believe that what we need is fair funding for the NHS—record funding for the NHS—and the best care for patients within the budget available. I know that the Liberal party has never been very keen on sound public finances or value for money, but the Government will continue to ensure that patients get the best possible value from the record investment that we have made.
Answered by
Patricia Hewitt
(Labour)
Asked by
David Heath
(Liberal Democrat)
Answering body
Department of Health
Type
Oral answers to questions
That was just typical: I asked three specific questions and received not a single reply from the Secretary of State. I thought that she would at least quote the results of the Health Service Journal survey of chief executives of trusts across the country, which revealed that 50 per cent. of primary care trusts are delaying operations; that 47 per cent. of all trusts may, have made or intend to make redundancies; and that 73 per cent. of PCTs are restricting access to treatment. Is not the conundrum this—that at a time when there is record cash going into the NHS and welcome investment in capital projects, we nevertheless have cuts in treatment? How can that be?
Subjects
Finance; NHS; Medical treatments; NHS trusts; Redundancy; Surgery
Date
13 March 2007
Reference
458 c150-1
Chamber / Committee
House of Commons chamber
House
House of Commons
As set out in the most recent financial report, it is now clear that the NHS will achieve the three financial targets set for this year while maintaining key service standards. Achieving financial balance this year means that the NHS will be in a far stronger position in the new financial year and, in particular, will be able to make substantial progress towards achieving the target of 18 weeks maximum from GP referral to hospital operation.
As set out in the most recent financial report, it is now clear that the NHS will achieve the three financial targets set for this year while maintaining key service standards. Achieving financial balance this year means that the NHS will be in a far stronger position in the new financial year and, in particular, will be able to make substantial progress towards achieving the target of 18 weeks maximum from GP referral to hospital operation.
Answered by
Patricia Hewitt
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
Subjects
Finance; NHS; Medical treatments; NHS trusts; Redundancy; Surgery
Date
13 March 2007
Reference
458 c150
Chamber / Committee
House of Commons chamber
House
House of Commons
What percentage of NHS trusts have (a) deferred operations, (b) made redundancies and (c) restricted provision of treatments in 2006-07 on grounds of reducing costs; and what percentage plan to do so in 2007-08.
What percentage of NHS trusts have (a) deferred operations, (b) made redundancies and (c) restricted provision of treatments in 2006-07 on grounds of reducing costs; and what percentage plan to do so in 2007-08.
Asked by
David Heath
(Liberal Democrat)
Answered by
Patricia Hewitt
(Labour)
Answering body
Department of Health
Oral questions - Lead
Status
Answered
Tabled on
7 March 2007
For answer on
13 March 2007
Answered on
13 March 2007
As set out in the most recent financial report, it is now clear that the NHS will achieve the three financial targets set for this year while maintaining key service standards. Achieving financial balance this year means that the NHS will be in a far stronger position in the new financial year and, in particular, will be able to make substantial progress towards achieving the target of 18 weeks maximum from GP referral to hospital operation.
Subjects
Finance; NHS; Medical treatments; NHS trusts; Redundancy; Surgery
Date
13 March 2007
Reference
458 c150; 126778
Chamber / Committee
House of Commons chamber
House
House of Commons
My hon. Friend is absolutely right, and I readily congratulate that team on its excellent research. The introduction of smoke-free legislation later this year will be an important step forward in public health generally, and specifically in reducing the risk of other people acquiring that appalling condition in future. We will, of course, redouble our efforts to get across the message about the huge dangers involved in smoking for people of any age.
My hon. Friend is absolutely right, and I readily congratulate that team on its excellent research. The introduction of smoke-free legislation later this year will be an important step forward in public health generally, and specifically in reducing the risk of other people acquiring that appalling condition in future. We will, of course, redouble our efforts to get across the message about the huge dangers involved in smoking for people of any age.
Answered by
Patricia Hewitt
(Labour)
Asked by
Brian Iddon
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
On the basis that prevention is better than cure, will my right hon. Friend congratulate Simon Kelly’s team at the Royal Bolton hospital, which has established a firm link between AMD and smoking? Does she agree that we should get the message across to all smokers in the land to try to avoid incidences of that difficult condition?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c693
Chamber / Committee
House of Commons chamber
House
House of Commons
The hon. Lady is right, because one has to look at the consequences for an individual and for social care and health services of a patient losing their sight. However, it really is not good enough for Conservative Members constantly to demand additional funding for new drugs, new treatments and additional services, when they have been wholly unwilling to support additional investment in the NHS—investment that we made and they voted against.
The hon. Lady is right, because one has to look at the consequences for an individual and for social care and health services of a patient losing their sight. However, it really is not good enough for Conservative Members constantly to demand additional funding for new drugs, new treatments and additional services, when they have been wholly unwilling to support additional investment in the NHS—investment that we made and they voted against.
Answered by
Patricia Hewitt
(Labour)
Asked by
Anne Milton
(Conservative)
Answering body
Department of Health
Type
Oral answers to questions
Does the Secretary of State agree that the cost of the drugs that can have a successful effect on people with conditions such as AMD are insignificant compared with the social costs of failing to treat such diseases?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c693-4
Chamber / Committee
House of Commons chamber
House
House of Commons
My right hon. Friend has raised an extremely important point. As he has said, Avastin has not been licensed for use on macular degeneration, although it is being used by some clinicians with the support of the NHS. The problem is that the companies concerned—Genentech which manufactures it and Roche which distributes it in Europe—have not applied for a licence for its use on macular degeneration, and no clinical trials have been conducted for that purpose. At the moment, if a clinician wants to use Avastin and the patient is willing to have an unlicensed drug used, it is available on the clinician’s judgment, which will continue to be the case within the NHS. Although we cannot require the companies concerned to apply for a licence, in view of the very promising results that have been reported by a number of doctors, I urge both companies to initiate clinical trials for the use of Avastin for people with macular degeneration and to consider applying for a licence in the light of those trials.
My right hon. Friend has raised an extremely important point. As he has said, Avastin has not been licensed for use on macular degeneration, although it is being used by some clinicians with the support of the NHS. The problem is that the companies concerned—Genentech which manufactures it and Roche which distributes it in Europe—have not applied for a licence for its use on macular degeneration, and no clinical trials have been conducted for that purpose. At the moment, if a clinician wants to use Avastin and the patient is willing to have an unlicensed drug used, it is available on the clinician’s judgment, which will continue to be the case within the NHS. Although we cannot require the companies concerned to apply for a licence, in view of the very promising results that have been reported by a number of doctors, I urge both companies to initiate clinical trials for the use of Avastin for people with macular degeneration and to consider applying for a licence in the light of those trials.
Answered by
Patricia Hewitt
(Labour)
Asked by
Kevin Barron
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
My right hon. Friend will know that wet AMD is also being treated at the moment on the NHS in some parts of the country by the use off-licence of a drug called Avastin that is licensed for the treatment of bowel cancer. When or if either of the drugs being appraised by NICE come into the marketplace with NICE’s approval, will Avastin still be available on the NHS if both the clinician and the patient believe that it should be?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692-3
Chamber / Committee
House of Commons chamber
House
House of Commons
No patient should be refused Lucentis or Macugen simply because NICE guidance does not yet exist, but NICE needs to evaluate the new treatments thoroughly and it has decided, I think rightly, to evaluate them together so that the two treatments can be compared with each other as well as with the existing treatment. That means that it is taking a little longer, although it started on the evaluation before Lucentis was licensed, as it was only a couple of weeks ago. The guidance will be ready as fast as possible, consistent with arriving at a good, thorough and fair decision.
No patient should be refused Lucentis or Macugen simply because NICE guidance does not yet exist, but NICE needs to evaluate the new treatments thoroughly and it has decided, I think rightly, to evaluate them together so that the two treatments can be compared with each other as well as with the existing treatment. That means that it is taking a little longer, although it started on the evaluation before Lucentis was licensed, as it was only a couple of weeks ago. The guidance will be ready as fast as possible, consistent with arriving at a good, thorough and fair decision.
Answered by
Patricia Hewitt
(Labour)
Asked by
Sandra Gidley
(Liberal Democrat)
Answering body
Department of Health
Type
Oral answers to questions
The Secretary of State will be aware that 57 people start to lose their sight daily through this condition, and the average annual cost of support is £9,500. Given that these therapies are widely regarded as being very effective, is there not a case for fast-tracking the NICE decision so that fewer people go blind?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692
Chamber / Committee
House of Commons chamber
House
House of Commons
Health is a devolved matter. At the moment, I understand that the health boards in Northern Ireland are not funding either Macugen or Lucentis. However, I am sure that they will want to take account of the NICE guidance, as soon as it becomes available.
Health is a devolved matter. At the moment, I understand that the health boards in Northern Ireland are not funding either Macugen or Lucentis. However, I am sure that they will want to take account of the NICE guidance, as soon as it becomes available.
Answered by
Patricia Hewitt
(Labour)
Asked by
Iris Robinson
(Democratic Unionist Party)
Answering body
Department of Health
Type
Oral answers to questions
What is the Secretary of State doing to ensure that people have the same opportunity to receive treatment for macular degeneration right across the country? In particular, Northern Ireland seems to be the last part of the United Kingdom to receive access to drugs, while others on the mainland benefit from them based on NICE guidelines.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c693
Chamber / Committee
House of Commons chamber
House
House of Commons
Just before Christmas, we reiterated guidance to the NHS that no patient should be refused Lucentis or Macugen, or indeed other treatments, simply because NICE guidance does not yet exist. Until NICE issues its guidance, as it will later this year, it is up to each primary care trust, whose professional executive is chaired by a clinician, to consider each case on an individual basis. The hon. Gentleman has to decide whether he supports NICE, which is widely regarded as a model around the world, or wants to go on undermining the outstanding and important work that it does.
Just before Christmas, we reiterated guidance to the NHS that no patient should be refused Lucentis or Macugen, or indeed other treatments, simply because NICE guidance does not yet exist. Until NICE issues its guidance, as it will later this year, it is up to each primary care trust, whose professional executive is chaired by a clinician, to consider each case on an individual basis. The hon. Gentleman has to decide whether he supports NICE, which is widely regarded as a model around the world, or wants to go on undermining the outstanding and important work that it does.
Answered by
Patricia Hewitt
(Labour)
Asked by
John Baron
(Conservative)
Answering body
Department of Health
Type
Oral answers to questions
As we have heard, despite Macugen being approved by the Scottish Medicines Consortium, and Lucentis receiving its European licence, neither drug will be appraised by NICE until later this year. Given the real concern felt by many—in particular, the Royal National Institute of the Blind and people such as Alice Mahon—that cash-strapped PCTs are withholding funding, and given the fact that the Government are not assessing what proportion of patients recommended for such treatments are being turned away, which is something that my PCT is struggling to answer, what concrete assurances can the Secretary of State give that PCTs are following her instruction that funding should not be withheld purely on the grounds that NICE has not yet issued its guidance?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c694
Chamber / Committee
House of Commons chamber
House
House of Commons
My hon. Friend has raised an extremely important point. Research on vision and on many medical conditions is the responsibility of the Medical Research Council, the funding for which we have significantly increased. I draw my hon. Friend’s attention to the review that we recently published of eye-care services, which emphasises the need to ensure that local primary care trusts get the best possible local eye-care services, with an emphasis on early diagnosis and better treatment in the community.
My hon. Friend has raised an extremely important point. Research on vision and on many medical conditions is the responsibility of the Medical Research Council, the funding for which we have significantly increased. I draw my hon. Friend’s attention to the review that we recently published of eye-care services, which emphasises the need to ensure that local primary care trusts get the best possible local eye-care services, with an emphasis on early diagnosis and better treatment in the community.
Answered by
Patricia Hewitt
(Labour)
Asked by
Sarah McCarthy-Fry
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
I think that the frightening thing is the speed with which the degeneration occurs—one of my constituents recently wrote to me about it. What are the Government doing to further research into vision and particularly into AMD? I welcome the Secretary of State’s statement on Lucentis today.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c694
Chamber / Committee
House of Commons chamber
House
House of Commons
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
Answered by
Patricia Hewitt
(Labour)
Asked by
Sandra Gidley
(Liberal Democrat)
Answering body
Department of Health
Type
Oral answers to questions
If she will make a statement on the treatment of age-related macular degeneration.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692
Chamber / Committee
House of Commons chamber
House
House of Commons
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
Answered by
Patricia Hewitt
(Labour)
Asked by
Michael Connarty
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
What provision her Department has made for funding treatments for macular degeneration; and if she will make a statement.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692
Chamber / Committee
House of Commons chamber
House
House of Commons
If she will make a statement on the treatment of age-related macular degeneration.
If she will make a statement on the treatment of age-related macular degeneration.
Asked by
Sandra Gidley
(Liberal Democrat)
Answered by
Patricia Hewitt
(Labour)
Answering body
Department of Health
Oral questions - Lead
Status
Answered
Tabled on
31 January 2007
For answer on
6 February 2007
Answered on
6 February 2007
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692; 118585
Chamber / Committee
House of Commons chamber
House
House of Commons
My hon. Friend is right that the Scottish Medicines Consortium has approved Macugen since August, although it has not arrived at any decision on Lucentis. Its view will be superseded by NICE guidance when it is available. The important thing is that decisions on the cost and clinical effectiveness of new drugs should be made by independent clinical authorities, not by politicians, and that is precisely why we established NICE and back it in making its judgments.
My hon. Friend is right that the Scottish Medicines Consortium has approved Macugen since August, although it has not arrived at any decision on Lucentis. Its view will be superseded by NICE guidance when it is available. The important thing is that decisions on the cost and clinical effectiveness of new drugs should be made by independent clinical authorities, not by politicians, and that is precisely why we established NICE and back it in making its judgments.
Answered by
Patricia Hewitt
(Labour)
Asked by
Michael Connarty
(Labour)
Answering body
Department of Health
Type
Oral answers to questions
I am sure that my right hon. Friend is aware that Macugen, an anti-vascular endothelial growth factor drug that can stop macular degeneration occurring in the eyes of elderly people, has already been approved in Scotland. As the increase of diabetes is likely to result in a vast increase in age-related macular degeneration, is it not time that the English authorities were allowed the same funding to give people the drug that is now available in Scotland?
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692
Chamber / Committee
House of Commons chamber
House
House of Commons
What provision her Department has made for funding treatments for macular degeneration; and if she will make a statement.
What provision her Department has made for funding treatments for macular degeneration; and if she will make a statement.
Asked by
Michael Connarty
(Labour)
Answered by
Patricia Hewitt
(Labour)
Answering body
Department of Health
Oral questions - Lead
Status
Answered
Tabled on
31 January 2007
For answer on
6 February 2007
Answered on
6 February 2007
All primary care trusts are funding photodynamic therapy for age-related macular degeneration in line with National Institute for Health and Clinical Excellence guidance. NICE is appraising Macugen and Lucentis for treating this condition and it expects to publish guidance in October.
Subjects
Finance; Medical treatments; Macular degeneration
Date
6 February 2007
Reference
456 c692; 118584
Chamber / Committee
House of Commons chamber
House
House of Commons
To ask the Secretary of State for Trade and Industry, what biotechnology research projects in (a) agriculture and (b) biomedics have been supported by her Department; and what level of public investment has gone into them in each of the last three years.
To ask the Secretary of State for Trade and Industry, what biotechnology research projects in (a) agriculture and (b) biomedics have been supported by her Department; and what level of public investment has gone into them in each of the last three years.
Asked by
Alan Simpson
(Labour)
Answered by
Patricia Hewitt
(Labour)
Answering body
Department of Trade and Industry
Type
Written questions
Status
Answered
Tabled on
22 July 2002
For answer on
19 September 2002
Answered on
19 September 2002
Alan Simpson: To ask the Secretary of State for Trade and Industry what biotechnology research projects in (a) agriculture and (b)
biomedics have been supported by her Department; and what level of public investment has gone into them in each of the last three
years. [73239]
Ms Hewitt: DTI has not funded any biotechnology research projects in agriculture. The Department has provided £5 million of funding
under the Applied Genomics LINK programme, which was launched in 2000, together with £10 million funding from the Research Councils,
to assist the exploitation of genomics for healthcare applications. In addition, a substantial part of the £25 million Harnessing
Genomics programme, launched by DTI in 2001, is providing support for industrially relevant R and D in key underpinning technology
areas, including bioinformatics and nanobiotechnology.
Subjects
Agriculture; Department of Trade and Industry; Biotechnology; Finance; Genetic engineering; Genetics; Medical treatments; Research
Date
19 September 2002
Reference
73239; 390 c164W
House
House of Commons